Altogether, it seems that the c-MYC intron retention, together with the lack of c-MYC legitimate transcriptional activity, can serve as a novel and powerful biomarker for human melanoma versus BCC and SCC skin cancers. This evidence concerns the gene MYC and skin cancer.